GT939

GT939 is a small molecule molecular glue degrader developed by Gluetacs Therapeutics that targets G1 to S phase transition 1 (GSPT1). GSPT1 is a translation termination factor that plays a critical role in protein synthesis and is frequently overexpressed in various malignancies. GT939 functions by facilitating a ternary complex between GSPT1 and an E3 ubiquitin ligase, typically cereblon (CRBN), leading to the polyubiquitination and subsequent proteasomal degradation of the target protein. This depletion of GSPT1 results in the inhibition of protein translation and the induction of apoptosis in cancer cells. GT939 is currently in preclinical development for the treatment of solid tumors.